Slide 1: Elevating the World's Wellbeing Q3 2022
Elevating the tŽƌůĚ͛Ɛ Wellbeing Q3 2022 (1 January 2022 ʹ 30 September 2022) Webcast presentation | November 7th 10:00 CET Q3
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as ͞ďĞůŝ
Slide 3: Agenda
Agenda Q3 in short Business update Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q3 in short
Q3 in short Q1 Q2 Q3 Q4 4
Slide 5: Continuing to be in line with mid term targets
65% 30% 46% Continuing to be in line Adjusted EBITDA Q3 YTD 2022 Q3 YTD 2022 YTD increased to with mid term targets revenue growth proforma revenue growth ΦϮ͘ϲŵ Quarterly progress Virtual Wellness Business Line Lifecare Technology Business Line - Continued investment in Access Ecosystem to broaden t
Slide 6: Business updates
Business updates } Physitrack Y
Slide 7: What we do
What we do Physitrack PLC, founded in 2012, is a global B2B digital healthcare provider, focused on providing technology to Care Providers and providing virtual-first Wellness solutions to Corporates. Elevating the ǁŽƌůĚ͛Ɛ wellbeing, the company has two business lines: Lifecare Technology Virtual We
Slide 8: Current state of play
Current state of play Revenue evolution EUR 13.0m (EURm) Wellness EUR 4.0m Lifecare Physitrack was born out of Technology Lifecare a desire to create a more EUR 5.3m Technology effective way to prescribe 89% exercise programs, as well Organic revenue EUR 9.0m as improve patient CAGR outcomes and red
Slide 9: Physitrack's M&A program – two years of enhancing our offering
WŚLJƐŝƚƌĂĐŬ͛ƐDΘƉƌŽŐƌĂŵʹ two years of successfully enhancing our offering May Reflecting on the past two years, Physitrack has implemented a 2022 very successful M&A program which: February Added two complementary businesses to expand the Lifecare Technology division 2022 Acquired four businesses
Slide 10: M&A program achievements
M&A program achievements Integration of Physitrack and Physiotools into one Lifecare technology powerhouse which at Q3 2022 boasts: - Φϴ͘ϳŵZZ - 48% Adjusted EBITDA (44%) Launch of PTCourses subscription model to mirror the other businesses within Lifecare Technology May 2022 Enhancement of library a
Slide 11: The world leader in Lifecare technology
The world leader in Lifecare technology. Supporting the patient journey every step of the way with a uniquely comprehensive solution. Q1 Q2 Q3 Q4 11
Slide 12: Lifecare Technology platform developments
Lifecare Technology platform developments Returns on investment 9% growth in license numbers within our Lifecare Technology businesses Successful transition of development team in-house with seventeen highly skilled tech developers joining Physitrack. 54,000 52,000 The new tech team has allowed
Slide 13: One platform. All areas of Wellbeing.
One platform. All areas of Wellbeing. Empowering employee wellbeing through data, insight and action. PREVENTION & POST-ACUTE, ANALYSIS & PREVENTION & FOLLOW-UP & WELLNESS POST-OP, CHRONIC ASSESSMENT WELLNESS (PHYSICAL) ANALYSIS (EMOTIONAL) CARE PROVISION Testing and assessment Technology-led exerci
Slide 14: Acceleration of growth in Wellness segment
Acceleration of growth in Wellness segment As we continue our unification of the Wellness segment by creating integrated care pathways from Growth, Wellness segment 3.0 the Access Ecosystem, during the quarter we have invested in tech and people to broaden the Champion Health offering to include: +5
Slide 15: Champion Health Mental Health Support Service
Champion Health Mental Health Support Service iv) The Mental Health pathways launched in Champion Health are a continuation of the integration journey of the Access ecosystem, available at at subscription fee to corporate customers in key markets. iv} Mental health-related absence is the most common
Slide 16: Financial Results
Financial Results Q1 Q2 Q3 Q4 16
Slide 17: Q3 Financial Highlights
Q3 Financial Highlights 9 month revenue 9 Month EBITDA 65% 340% Φ9.0m (Q3 2021͗Φ5.4m) Φϭ͘Ϯŵ (Q3 2021: ΦϬ͘ϯŵ) Operating cashflow 9 month proforma 30% 100% revenue growth Φ0.6m (Q3 2021͗Φ0.3m) 9 month adjusted EBITDA 9 month adjusted EBITDA margin 46% Φ2.6m (Q3 2021͗Φ1.8m) 29% (Q3 2021: 32%) 3pp Q1 Q2
Slide 18: Maintaining revenue growth
Maintaining revenue growth In-line with medium term growth targets Group Revenue Lifecare technology revenue growth Virtual Wellness revenue growth 2.5 4.0 2.5 3.5 17% 2.0 28% 3.0 2.0 72% 2.5 Euro Million 1.5 Euro Million Euro Million 1.5 2.0 1.0 1.5 1.0 57% 1.0 0.5 0.5 0.5 - - - Q1 2021 Q2 2021 Q3
Slide 19: EBITDA
EBITDA Strong growth 3.0 2.5 46% 2.0 Φ1.3M Φ͛ŵŝůůŝŽŶ 1.5 Φ2.6M Φ1.8M 1.0 Φ1.5M ADJUSTED EBITDA Margin ADJUSTED EBITDA 32% Margin 340% Φ1.2M 29% 0.5 ΦϬ͘ϯŵ - 9 MONTHS 2021 EBITDA Adjusting items* 9 MONTHS 2021 Adjusted 9 MONTHS 2022 EBITDA Adjusting items* 9 MONTHS 2022 Adjusted EBITDA EBITDA *Adjusti
Slide 20: EBITDA by division
EBITDA Strong growth 3.0 2.5 46% Adjusted EBITDA by division 0.8 2.0 0.9 3.1 Margin 48% Q3 YTD 2022 0.1 Margin 3% Φ͛ŵŝůůŝŽŶ Margin (0.6) 1.5 0.7 (6)% 0.9 Margin 2.2 1.0 44% Margin Q3 YTD 2021 0.0 0.6 7% Margin (9)% (0.5) 0.5 0.7 (1.0) (0.5) - 0.5 1.0 1.5 2.0 2.5 3.0 3.5 0.5 Lifecare technology Virtu
Slide 21: Cashflow
18.0 CASHFLOW 16.0 Cash reinvested in investing activities (0.8) (0.1) 2.6 14.0 (3.2) 12.0 10.0 Φ͛ŵŝůůŝŽŶ (6.9) 8.0 13.3 6.0 4.0 Φϰ͘ϳŵƵŶĚƌĂǁŶŽŶ facility 4.7 ( 3.4 ) 2.0 0.1 (1.2) 0.8 1.1 - 1 Jan 2022 Opening Adjusted EBITDA Working capital Interest expense Purchase of Acquistions net of Deferred M&A
Slide 22: Balance Sheet
Balance Sheet Net assets position strengthened from goodwill and intangibles recognized on acquisitions 30 September 2022 31 December 2021 ƵƌŽƐ͚ϬϬϬ Goodwill, intangibles and PPE 37,791 17,221 Cash and cash equivalents 1,075 13,325 Borrowings (822) (1) Trade and other receivables 3,432 1,666 Inventor
Slide 23: Strategy and outlook
Strategy and outlook Q1 Q2 Q3 Q4 23
Slide 24: Executing a well-defined growth plan combining organic and inorganic initiatives
Executing a well-defined growth plan combining organic and inorganic initiatives Planning to build a global powerhouse in the remote physical care space through well-defined, tangible organic and inorganic growth objectives 3 M&A initiative 2 Continue strong M&A integration to Organic growth levers
Slide 25: A robust business model, able to withstand headwinds
A robust business model, able to withstand headwinds Balanced portfolio Our geographical diversity and varied revenue streams make the business robust - dramatic changes in the world do not necessarily affect all parts of our business Profitable growth is part of our DNA Our organisation is cost opt
Slide 26: Financial goals – What we aim for
Financial goals ʹ What we aim for Top-line growth Profit margins Value creation/distribution Physitrack aims to achieve annual Physitrack targets an EBITDA margin Physitrack aims to reinvest profits organic sales growth exceeding 30% of 40-45% in the medium term, with and cash flows in organic growt
Slide 27: Q&A
Q&A Q1 Q2 Q3 Q4 27